ArticleGut microbes
The colibactin-producing
Open access · goldAbstract read
In one paragraph
Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
21.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Guideline for designing microbiome studies in neoplastic diseases.GeroScience · 2024Guideline
- Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy.Gut microbes · 2026Review
- Colorectal cancer landscape from gut microbiota: Insights into mutations, epigenetic dysregulation, and immune microenvironment alterations.Virulence · 2026Review
- Review
- Unveiling the association between plasma lipid species and pan-cancers: A bidirectional 2-sample Mendelian randomization study.Medicine · 2026Article
- Apurinic/apyrimidinic endonuclease 1 prevents oxidative DNA damage in intestinal epithelial cells induced by genotoxic Escherichia coli NC101.Redox biology · 2026Article
- Mechanisms and advances of drug resistance in colorectal cancer: A systematic overview of multi-layered regulatory networks.Translational oncology · 2026Review
- Intratumoral microbiota in colorectal cancer: roles, therapeutic potential, and challenges.Journal of advanced research · 2026Review
- Synthetically engineered probiotic suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling.Cell reports. Medicine · 2026Article
- Microbiome-Shaped Metastatic Niches in Colorectal Cancer: Organ-Specific Patterns, Immune-Metabolic Mechanisms, and Therapeutic Translation.Microorganisms · 2026Review
- Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential.Genes & diseases · 2026Review
- Stage-Specific carcinogenic mechanisms and intervention strategies for pksArchives of microbiology · 2026Review
- Spatial Heterogeneity of Intratumoral Microbiota and Its Roles in Tumor-Microbiota Interactions and Therapeutic Implications.Pathogens (Basel, Switzerland) · 2026Review
- Research advances in the role of circulating microorganisms in gastrointestinal tumors (Review).Molecular and clinical oncology · 2026Review
- The Role of Selected Bacteria in Breast Cancer Initiation and Development.International journal of molecular sciences · 2026Review
- Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies.MedComm · 2026Review
- Anti-Cancer Effects of Quercetin: What Role Does the Gut Microbiota Play?Molecules (Basel, Switzerland) · 2026Review
- Tumor exosomes impact functional hallmarks of cancer.Cancer metastasis reviews · 2026Review
- Bacteriophages as Antibacterial Agents Against Bovine Pathobionts Associated with Foodborne Human Morbidity.Viruses · 2026Review
- Targeting Intratumoral Bacteria for Enhanced Tumor Suppression with Nano-Based Therapeutics: A Scoping Review.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 7 institutions in 3 countries.
Nilmara de Oliveira AlvesONCOLille, INSERM, Phycell, University of Lille, Lille, France.ORCID 0000-0003-0400-882X
Guillaume DalmassoMicrobes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
Darja NikitinaCNRS, Institute Pasteur, Paris, France.
Amaury VaysseInstitut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
Richard RuezONCOLille, INSERM, Phycell, University of Lille, Lille, France.
Lea LedouxRéponse Inflammatoire et Spectrométrie de Masse-PRISM, University of Lille, Lille, France.
Thierry PedronInstitut Pasteur, Inserm, Paris, France.
Emma BergstenInstitut Pasteur, Université Paris Cité, Paris, France.
Olivier BoulardONCOLille, INSERM, Phycell, University of Lille, Lille, France.ORCID 0000-0002-4376-046X
Lora AutierONCOLille, INSERM, Phycell, University of Lille, Lille, France.
Sofian AllamONCOLille, INSERM, Phycell, University of Lille, Lille, France.
Laurence MotreffInstitut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
Pierre SauvanetMicrobes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
Diane LetourneurInstitut Pasteur, Université Paris Cité, Paris, France.
Pragya KashyapDepartment of Bioscience & Bioengineering, Indian Institute of Technology, Jodhpur, Rajasthan, India.
Johan GagnièreMicrobes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
Denis PezetMicrobes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
Catherine GodfraindMicrobes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
Michel SalzetRéponse Inflammatoire et Spectrométrie de Masse-PRISM, University of Lille, Lille, France.
Emmanuel LemichezInstitut Pasteur, Université Paris Cité, Paris, France.
Mathilde BonnetMicrobes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
Imène NajjarInstitut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
Christophe MalabatInstitut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
Marc MonotInstitut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
Denis MestivierUniversité Paris Est Créteil, Créteil, France.
Nicolas BarnichMicrobes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
Pankaj YadavDepartment of Bioscience & Bioengineering, Indian Institute of Technology, Jodhpur, Rajasthan, India.
Isabelle FournierRéponse Inflammatoire et Spectrométrie de Masse-PRISM, University of Lille, Lille, France.
Sean KennedyCNRS, Institute Pasteur, Paris, France.
Amel MettouchiInstitut Pasteur, Université Paris Cité, Paris, France.
Richard BonnetMicrobes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
Iradj SobhaniUniversité Paris Est Créteil, Créteil, France.
Mathias ChamaillardONCOLille, INSERM, Phycell, University of Lille, Lille, France.ORCID 0000-0002-0243-9717
Institut Pasteur · FRUniversité Clermont Auvergne · FRInserm · FRUniversité de Lille · FRCentre National de la Recherche Scientifique · FRIndian Institute of Technology Jodhpur · INUniversité Paris-Est Créteil · FR
Funding
Epigenetic mechanisms of carcinogenesis by Parvimonas micra, an oral cavity commensal turned colon cancer pathogenR01CA264048 · NCI · MAYO CLINIC ARIZONA · PI BOARDMAN, LISA ALLYN, GOUNARI, FOTINI · 2021 to 2025
$3.1MNCI NIH HHS R01 CA264048
Abstract
Intratumoral bacteria flexibly contribute to cellular and molecular tumor heterogeneity for supporting cancer recurrence through poorly understood mechanisms. Using spatial metabolomic profiling technologies and 16SrRNA sequencing, we herein report that right-sided colorectal tumors are predominantly populated with Colibactin-producing
Indexed as
Colorectal NeoplasmsGastrointestinal MicrobiomePeptidesPolyketidesDrug Resistance, NeoplasmEscherichia coliHumansLipidsMutagensNeoplasm Recurrence, LocalTumor MicroenvironmentcolibactinLipidsMutagensPeptidesPolyketidesColibactin-producing Escherichia coliland’s cyclelipid dropletright-sided colorectal cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.